Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA,...
Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026
Clinically Meaningful Overall Antitumor Activity, with ORR of 42.9% and DCR of 95.9% across all evaluated dose levels in heavily pretreated patients. Enhanced Clinical Activity at the Recommended Phase 2 Dose (RP2D), with ORR of 50% in patients who...
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO, June 1, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate...
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease...
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line KRAS...
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI In treatment-naive patients with advanced NSCLC...
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the...
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncology...
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual...
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506)...